Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic, Minnesota, United States
S. Vincent Rajkumar, M.D., is the Edward W. and Betty Knight Scripps Professor of Medicine and is a Mayo Clinic Clinician Investigator. His academic career was profiled by The Lancet: Nov 26th 2011 issue. Dr. Rajkumar chaired the Mayo Clinic Myeloma /Dysproteinemia Clinical Committee from 2006-2016.He is co-chair of the International Myeloma Working Group (IMWG), and Chair of the Eastern Cooperative Oncology Group (ECOG) myeloma committee. He serves as the Editor in Chief of Blood Cancer Journal, and Associate Editor for: Mayo Clinic Proceedings, Leukemia, and European Journal of Hematology. Dr. Rajkumar serves on the board of directors for the International Myeloma Foundation and is a member of the National Institutes of Health’s Multiple Myeloma Steering Committee. He is the recipient of the Robert A. Kyle Lifetime Achievement Award (2016), Relentless for a Cure Award (2010), John Ultmann Lecture and Award (2011), Janet Davison Rowley Patient Impact Research Award (2015), Giants of Cancer Care Award (2019), and the Jan Waldenstrom Lifetime Achievement Award (2021). He was named Mayo Clinic Distinguished Investigator in 2018.
Dr. Rajkumar is recognized internationally as a leading authority in the field of plasma cell disorders. His scientific contributions include clinical trials, epidemiological studies, and laboratory research focused on myeloma and related disorders. He led the pivotal trial that led to the approval of thalidomide for the treatment of multiple myeloma in the United States. He has also led several large studies on the prevalence and progression of monoclonal gammopathies, racial disparities in the incidence of myeloma, and familial predisposition. Dr. Rajkumar has identified several biomarkers that are used in the diagnosis and risk stratification of plasma cell disorders. He has over 700 publications, including over 450 peer-reviewed original research papers, and over 200 reviews and book chapters.
Newly Diagnosed Multiple Myeloma
Wednesday, September 27, 2023
3:30 PM – 5:30 PM EEST
Wednesday, September 27, 2023
4:45 PM – 5:00 PM EEST
Wednesday, September 27, 2023
6:45 PM – 7:30 PM EEST